Dr Tomas Stojanov, PhD
CEO of Genea Limited
Dr Stojanov has over 26 years experience in diverse aspects of the health, biotechnology and agriculture sectors from the perspective of scientific research, operational management and technology commercialisation.
Dr Uli Schmidt, PhD
General Manager – Genea Biocells
Dr Schmidt has a
longstanding interest in the development of novel drug discovery-related
technologies with a strong focus on entrepreneurship. His
scientific expertise includes molecular and cell biology as well as assay
development, high-throughput screening and high-content analysis. He is an
inventor on nine Australian and international patents and the author of 16
original research publications. Prior to joining Genea (formerly Sydney IVF) in
2007, he was the co-founder of Dimerix Bioscience, a company based on novel
GPCR drug screening technologies and the scientific founder of a European diagnostics/drug delivery company. Dr Schmidt is now an executive of Genea Limited
and as General Manager of Genea Biocells shapes the company’s scientific
direction and advances its business development.
Dr Julia Schaft, PhD
Manager of Strategy and Regulation – Genea Biocells
Dr Julia Schaft, PhD, has a background in developmental and molecular biology. She obtained her PhD at the University of Giessen and the European Molecular Biology Laboratory (EMBL) and has gained experience in animal stem cell techniques, as well as transgenic mouse production. After joining Genea in 2004 as a stem cell research scientist, Dr Schaft was trained in human embryonic stem cell techniques and has played a key role in securing funding and other opportunities furthering Genea’s stem cell business strategy. Dr Schaft manages all of Genea’s embryo research licences and provides expert advice on all ethical matters involving research. She assists in identifying and facilitating strategic alliances with international pharmaceutical and academic partners to further the development of embryonic stem cell driven disease research and drug development.
Professor Alan Colman
Alan Colman is currently a Principal Investigator in the Singapore A*STAR Institute of Medical Biology and also Executive Director of the Singapore Stem Cell Consortium. In the mid 1990’s, working with researchers at the UK Roslin Institute who pioneered the technique of somatic cell nuclear transfer (SCNT) in mammals, Prof Colman jointly managed the program that led to Dolly, the world's first cloned sheep and reproductive SCNT in various other large animal species.
Mr Euan Pizzey
As director of finance for Vision Systems Ltd, then a large ASX listed histopathology and contract R&D group, Mr Pizzey gained specialist expertise in the areas of strategic and business planning, business restructure, business valuations, mergers and acquisitions, core technology valuations, R&D syndicate financing, capital raising and structured finance.
Dr Dianne Glenn
As Principal of Corelli Consulting, Dr Glenn has been involved in diverse aspects of technology commercialisation, from scientific research to investment and corporate activities within government and academic research institutes and the private biotech sector. Dianne holds a PhD in molecular biology and is an invited lecturer at the School of Biotechnology and Biomolecular Sciences at the University of NSW. On behalf of Corelli Consulting, Dianne Glenn has provided advice on technology and partner due diligence, merger and acquisition transactions, Initial Public Offerings, as well as the investment readiness of listed biotechnology companies.